Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Foxwoods Man, drkazmd65
Search This Board:
Last Post: 8/28/2014 7:31:10 AM - Followers: 158 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/



Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
  2. The scientific, clinical, and commercial development of the medicine and
  3. CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  
  2. Teva Pharmaceuticals Industries Ltd.
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  
  3.  
  4. Orient Europharma Co. Ltd.
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  
  5.  
  6. IDC-GP Pharm LLC 
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  
  7.  

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
Wiki
CVM News: Statement of Changes in Beneficial Ownership (4) 08/28/2014 05:50:07 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 08/25/2014 12:50:20 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 08/21/2014 12:09:42 PM
CVM News: Securities Registration: Employee Benefit Plan (s-8) 08/19/2014 05:41:22 PM
CVM News: CEL-SCI Expands its Global Phase III Immunotherapy Head & Neck Cancer Trial into Centre Hospitalier Universitaire de Quebec i... 08/19/2014 08:00:00 AM
PostSubject
#6215  Sticky Note http://www.marketwatch.com/story/small-companies-lead-the-i-o-class-of-cancer-th majatamata 08/08/14 11:00:50 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#6254   I totally agree and I do think that Foxwoods Man 08/28/14 07:31:10 AM
#6253   Some speculators' estimates of where CVM 'should' be drkazmd65 08/28/14 01:02:42 AM
#6252   The problem with the Yahoo 1 yr. target Foxwoods Man 08/26/14 09:01:17 AM
#6251   I hope Foxwoods will add his .04 cents. mtber 08/26/14 08:14:07 AM
#6250   Any theories or ideas as to why or pijoe 08/25/14 12:41:58 PM
#6249   Add another site. goodplenty100 08/19/14 09:40:39 AM
#6248   More excellent news! drkazmd65 08/19/14 09:28:28 AM
#6246   Add another site: Foxwoods Man 08/19/14 08:19:26 AM
#6245   Interesting exerpts of past articles re: CVM arbitration: Foxwoods Man 08/18/14 02:20:37 PM
#6244   Usually that is the case FM - but drkazmd65 08/18/14 02:12:29 PM
#6243   From what I understand going to an arbitrator Foxwoods Man 08/18/14 01:40:13 PM
#6242   Chances are Jukimol - that if it looks drkazmd65 08/18/14 10:13:12 AM
#6241   The fact that the arbitrator dismissed all the Jukimol 08/15/14 01:26:48 PM
#6240   Interesting that it is still in the "preliminary Foxwoods Man 08/13/14 03:29:11 PM
#6239   An interesting Tidbit from the most recent 10-q drkazmd65 08/13/14 01:08:15 PM
#6238   My Pleasure MM goodplenty100 08/12/14 04:23:27 PM
#6237   Thanks for the link goodplenty. drkazmd65 08/12/14 11:48:44 AM
#6236   http://seekingalpha.com/article/2414125-cel-sci-is-a-leader-in-the-i-o-class-of- goodplenty100 08/12/14 11:10:32 AM
#6235   No he has to file as he owns ID Supermoney 08/10/14 10:26:23 PM
#6234   K. Almost there turbo friend....when he took his learning curve 08/10/14 10:18:06 PM
#6233   If threshold is 5% then they use the ID Supermoney 08/10/14 10:00:15 PM
#6232   Institutional holdings = TUT's ID Supermoney 08/10/14 09:58:17 PM
#6231   What is TUT financing mean? Never heard that learning curve 08/10/14 09:56:19 PM
#6230   I'm a bit confused; not sure if my learning curve 08/10/14 09:51:06 PM
#6229   Because this is a listed company!! Not an OTCBB ID Supermoney 08/10/14 09:34:47 PM
#6228   Here is the link for guy whom i learning curve 08/10/14 09:27:13 PM
#6227   True - they are bonus shares. drkazmd65 08/10/14 12:10:28 PM
#6226   I will agree..that is a HUGE amount of Foxwoods Man 08/10/14 07:50:49 AM
#6225   We see about $6.5-7.0 million burn every 3 months!! ID Supermoney 08/09/14 11:15:39 PM
#6224   So on June 30, 2014 we have ($0.80 ID Supermoney 08/09/14 11:11:46 PM
#6223   I have couple questions? learning curve 08/09/14 10:15:36 PM
#6222   These GUYS DID NOT BUY over 14.2 million shares!! ID Supermoney 08/09/14 07:23:00 PM
#6221   Somethings going on. The officers just bought over majatamata 08/09/14 04:01:18 PM
#6220   Nice find....interesting that the company with the product Foxwoods Man 08/08/14 02:13:20 PM
#6219   Nice info..Thanks majatamata 08/08/14 11:52:44 AM
#6218   The big issue (IMO) here is a lot drkazmd65 08/08/14 11:46:31 AM
#6217   I hope it gets around and we can majatamata 08/08/14 11:27:09 AM
#6216   Nice find majatamata - you beat me to drkazmd65 08/08/14 11:20:34 AM
#6215   http://www.marketwatch.com/story/small-companies-lead-the-i-o-class-of-cancer-th majatamata 08/08/14 11:00:50 AM
#6214   I waiting to be rewarded with those sub-dollar shares. kpisme 08/07/14 04:19:41 PM
#6213   Long, complicated, form 8K filed today - formatting drkazmd65 08/07/14 04:16:44 PM
#6212   Well....an agenda is an agenda so let's just Foxwoods Man 08/07/14 07:42:41 AM
#6211   He reiterated his position. You don't know if learning curve 08/06/14 10:31:32 PM
#6210   Back in April you said CVM would fall Foxwoods Man 08/06/14 07:06:42 AM
#6209   This is going down to $1.00 and lower! ID Supermoney 08/06/14 01:19:46 AM
#6208   A superb 'well done' to you. The most mogman 08/04/14 05:11:59 PM
#6207   I hadn't heard of the company that makes drkazmd65 08/04/14 02:50:36 PM
#6206   drkazmd65... With all due respect to your knowledge mogman 08/04/14 02:21:31 PM
#6205   We can use L.E.A.P.S to cure Ebola. drkazmd65 08/04/14 11:38:26 AM
#6204   We can use L.E.A.P.S to cure Ebola. Turney 08/02/14 11:17:19 AM
PostSubject